Clinical Phase III

ARTICLES

  • Developing A Strategic Relationship – Amgen And PRA

    When new opportunities arise and sponsor companies are vetting CROs or partners for their work, they look first to their existing relationships. Then, particularly for new development areas such as biosimilars, they look at the entire landscape for other organizations that have specific expertise in that field. By Rob Wright

  • Kemwell Overview Manufacturing customers include top pharmaceutical companies – Allergan, Bayer, GSK, J&J, Pfizer, Teva, and Novartis, as well as small emerging biotech.

SUPPLIER PROFILES

  • Signant Health, formerly CRF Bracket

    The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials.

  • Kemwell Biopharma

    With manufacturing locations in Bangalore India, and Uppsala Sweden, Kemwell offers the entire value chain from early & late stage drug development services, clinical trial supply support, to commercial contract drug manufacturing.

  • Pharma Tech Industries

    For more than 35 years, Pharma Tech Industries has built an outstanding reputation as a family-owned business, providing exceptional contract development, contract manufacturing and contract packaging services to the world's leading pharmaceutical, medical devices and consumer products companies.

  • Uman Pharma Inc.

    Uman Pharma is a fully-integrated pharmaceutical company that develops, manufactures and markets generic injectable pharmaceutical products and is the only oncology plant in Canada featuring freeze dryer and pre-filled syringes capacity.

  • UPM Pharmaceuticals, Inc.

    UPM Pharmaceuticals, Inc. is a Baltimore-based, independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries.

SERVICES

  • Cadiovascular Clinical trials in the cardiovascular space have become more complex. You may be facing limited access to capital, growing scrutiny from pharma partners and payers, as well as new requirements from regulatory agencies — all with limited operational resources.
  • Point Of Care: Cardiac Biomarker Tests Point of Care Cardiac Biomarker tests include Troponin I, CK-MB, BNP, Pro-BNP, D-Dimer and Myoglobin, with results in minutes.